Entavir 0.5 mg | Anti viral drugs

  • Entavir 0.5mg tablet are used as anti-viral medicine, the safety and effectiveness of the Entavir 0.5mg has been established against chronic hepatitis B viral infection. Entavir 0.5mg contains an active compound known as Entecavir. Entavir 0.5mg is a classified as prototype for cyclopentane class of nucleoside or nucleotide long lasting hepatitis B anti-viral drug. Entavir 0.5mg tablets are nor curable, may it used to reduce the amount of HBV virus in the body Entavir diminishing the capability of HBV for multiplication and infecting new liver cells Entavir 0.5mg enhance the condition of liver Entavir 0.5mg used to reduce the chance of getting liver cancer & liver failure due to hepatitis B infection in chronic.
Entavir 0.5mg , Entavir 0.5mg tablet

INDICATION

The major usage of Entavir 0.5mg tablet are; Entavir 0.5mg tablets are involved in the treatment of chronic hepatitis B viral infection in adults and pediatric patients with the age of 2 years and older with the sign of active viral production, either constant eminence of serum aminotransferase or histological effective disease. Before initiating the therapy with Entavir 0.5mg tablets, the crucial points should be considered; The evidence of Entavir 0.5mg in adult patients based on the clinical trial data in nucleoside inhibitor therapy for new patients and patient opposed to lamivudine treatment with HBeAg positive and HBeAg negative HBV infection and compensated liver cirrhosis & minor in decompensated cirrhosis. In children with the age of 2 years or older: Used for nucleoside inhibitor therapy naïve, lamivudine resistance patients with HBeAg positive chronic HBV infection and compensated cirrhosis patients.

DOSAGE

The dosage recommendation of Entavir tablets are given below as follows :

  • In compensated liver disease : The usual dosage of Entavir 0.5mg tablet for this condition in adults is 0.5mg should be recommended as a single dose.
  • In decompensated cirrhosis: In chronic hepatitis B viral infected patients, the prescribed dosage of Entavir is 1mg should be given orally as a single dose.

In pediatric patients :

  • For therapy naïve patients : The recommended dosage of Entavir 0.5mg tablet should be given as a single dose.
  • For lamivudine resistance : The prescribed dosage is 1mg of Entavir should be taken as a single dose.
  • For renal impairment patients : CrCl 50ml/min or greater: The recommended dosage is 0.5mg of Entavir given as a single dose CrCl 30 to less than 50ml/min: The recommended dosage is 0.5mg of Entavir given for every 48 hours CrCl 10ml/min to less than 30ml/min: The prescribed dosage is 0.5mg of Entavir should be given for every 72 hours. CrCl less than 10ml/min & hemodialysis, CAPD: The suggested dosage is 0.5mg of Entavir given for every 7 days.
  • In lamivudine resistant or decompensated cirrhosis : CrCl 50ml/min or greater: The recommended dosage is 1mg of Entavir 0.5mg given as a single dose CrCl 30 to less than 50ml/min: The recommended dosage is 0.5mg of Entavir given as a single dose or 1mg for every 48 hours. CrCl 10ml/min to less than 30ml/min: The prescribed dosage is 1mg of Entavir should be given for every 72 hours. CrCl less than 10ml/min & hemodialysis, CAPD: The suggested dosage is 1mg of Entavir given for every 7 days.
  • How to administer Entavir 0.5mg tablets : Entavir tablet should be given for chronic hepatitis B viral infected patients, taken in an empty stomach i.e., partially 2 hours after a meal and 2 hours earlier the next meal.

ADME

For chronic hepatitis B viral infection, using Entavir 0.5mg tablets after an oral administration undergoes absorption, distribution, metabolism & elimination. Entecavir Peak plasma concentration time of Entavir 0.5mg is 0.5 hour & 1.5 hours 0.5mg of Entavir 0.5mg tablets: The steady state occurs at 4.2ng/ml and Ctrough is 0.3ng/ml Bounding of Human plasma protein is 13%. After attaining peak plasma concentration time, the plasma concentration of Entecavir is reduced in bi exponential aspect. The terminal half life period of Entavir 0.5mg tablet is 128 to 149 hours Entavir 0.5mg is excreted via kidneys with the range of 62% to 73% in unchanged form. Renal clearance value 360ml/min to 471ml/min.

WORKS AS

Entavir enclose as Entecavir as an active component, a synthetic analogue of 2-deoxyguanosine has anti-viral activity against hepatitis B virus. Entecavir is triggers in-vivo into 5-triphosphate metabolite which is an active form of Entecavir. Successively, the active metabolite triphosphate form strike with natural substrate deoxyguanosine triphosphate dGTP for infusion into viral DNA. Hence infusion of the activated triphosphate metabolite of Entecavir leads to inhibition of reverse transcriptase enzyme. For viral production and transcription RT is required, thus inhibition results as cell lysis.

PRECAUTIONS

  • There are two major unfavorable conditions may occur during or after discontinuation of therapy with Entavir 0.5mg tablets. It may include as :
  • Hepatitis B aggravation occurs severely after therapy Lactic acidosis or hepatomegaly with steatosis In lactic acidosis or hepatomegaly with steatosis :
  • Nucleoside analogue inclusive of Entavir 0.5mg , using alone or combination with other anti-retroviral medicines, reported has fatal cases like lactic acidosis or hepatomegaly with steatosis. This condition is majorly occurs in women, causes obesity and extended nucleoside inhibitor risk. Discontinue the therapy If this adverse effect occurs or otherwise provide supportive measures.
  • In hepatitis B reactivation : This side effect occurs mostly after the stopping of anti-hepatitis B viral therapy frequently. Hepatic or liver function test should be periodically taken for the patients To avoid this condition, The patients who are getting hepatitis B infection after the treatment, recurrently will get Anti-hepatitis B viral therapy
  • In patients with HBV/HIV co infection : Entavir 0.5mg usage is not assessed in HBV/HIV co infected patients who are not correspondingly getting anti-retroviral medication. Entavir 0.5mg tablets used to treat chronic hepatitis B infection in HIV infected patients that are not being used if there is a possible to get advancement of resistance to HIV nucleoside reverse transcriptase inhibitors. Patient must investigate by checking the HIV antibody before starting therapy with Entecavir Entavir 0.5mg causes some effects due to interact with other drugs; Concurrent use of Entavir 0.5mg with lamivudine, Adefovir or tenofovir disoproxil fumarate cause no serious drug interactions Some drugs may cause some effects while concomitant with Entecavir, it may follow as; Chlorpheniramine Ginkgo Biloba Aspirin Lamivudine Metoprolol Valproate sodium Paracetamol, Sorafenib, KCl in sodium chloride Hence, Entavir 0.5mg is eliminated after metabolism through kidneys. If co administration of Entavir 0.5mg tablets with drugs reducing the renal function may leads to cause increasing the concentration of Entecavir and produces serious adverse effects.

MISSED DOSE

  • Entavir 0.5mg tablet are anti-hepaciviral drug, used only by getting advice from medical practitioner. 
  • If patient fail to take the dose of Entavir 0.5mg , should consult with physician and follow the instructions given by them or otherwise swap the missed dose and continue the regular dosing schedule.

CONTRAINDICATIONS

  • Entavir 0.5mg has no contraindications Some hypersensitivity reactions may occur, if patients are contraindicated to component of Entavir 0.5mg tablets.

OVERDOSAGE

  • Over dosage is not occurred during the therapy using with Entavir 0.5mg tablets. If over dosage occurs, the patients must be confirmed with toxicity and monitored the signs and symptoms. 
  • Patients should be provided with supportive measures For single dose of 1mg of Entecavir, after 4hours of hemodialysis clears 13% of Entecavir dose from the body.

STORAGE

  • Entavir 0.5mg tablet should be stored at 20℃ to 25℃ (68℉ to 77℉) Protected away from moisture, heat and light.

EFFECT OF FOOD

While taking Entavir 0.5mg tablet with high fat meal causes reduction of absorption of Entecavir. Entavir 0.5mg must be administered on an empty stomach.

Entavir 0.5mg , Entavir 0.5mg tablet

SIDE EFFECTS

  • Two major adverse effects occurred after completion of therapy, includes as Lactic acidosis or severe hepatomegaly with steatosis Aggravation of hepatitis B viral infection after anti-hepatitis B viral treatment discontinued. Most common side effects in compensated liver cirrhosis are : Headache, Fatigue, Dizziness, Hematuria, Abnormal lab test results may occur, Diarrhea, Dyspepsia, Vomiting, Insomnia, Hepatic encephalopathy, Creatinine value get elevated, Hyperglycemia, Respiratory tract infection, Depletion of blood bicarbonate, Renal failure, Hepatorenal syndrome, Gastrointestinal hemorrhage, Hepatocellular cancer, Immune system related effects like anaphylactic reaction, Skin: Alopecia, rash, Elevation of AST and ALT.

In decompensated cirrhosis :

  • Peripheral edema, Ascites, Pyrexia, Glycosuria.

CONTACT DETAILS

Phone: + 91-9987711567

Email: applepharmaceutical@gmail.com

Email: info@myapplepharma.com

Website:  https://myapplepharma.com/entavir-0.5mg.php

Taffic 25mg/200mg/50mg |Taffic Hetero |Myapplepharma

  • Taffic is an anti-retroviral drug containing three prominent factors is known as; Tenofovir Alafenamide Emtricitabine Bictegravir Tenofovir Alafenamide is a nucleotide transcriptase inhibitor Emtricitabine is a nucleoside reverse transcriptase inhibitor Bictegravir is an integrase inhibitor.
  • These are the most effective & a potent compound against HIV-1 infections, but it does not cure the infection situation it is only used for preventing & suppressing the evolution of HIV-1 infection into AIDS. In Taffic tablet , TAF is present as a prodrug. 
  • Emtricitabine is synthetics fluoro derivative of thiacytodone. Bictegravir is an investigational drug.
Taffic , Taffic tablet

INDICATIONS

Taffic is a combination tablet contains Tenofovir Alafenamide, Emtricitabine & Bictegravir is mainly indicated for the treatment of HIV-1 infection in adult’s patients.

DOSAGE

  • The prescribed dose of Taffic is one tablet that should be given orally as day-to-day. Important points; before starting the treatment, the patient should be considered for the presence of hepatitis B infection or not.
  • The patient’s renal values should be investigated for the creatinine approval, urine glucose & urine protein. Taffic should be used in adolescents, a pediatric patient with weighing at least 25kg & creatinine clearance of patients should be larger or equal to 30ml/min.
  • Taffic should not be suitable for patients with creatinine clearance below 30ml/min. Taffic tablet should be executed with food or without food.

PHARMACOLOGY

  • Taffic is a nucleoside reverse transcriptase inhibitor (carboxylic synthetic nucleoside analog), it has activity against human immunodeficiency virus type I.
  • Taffic tablet is phosphorylated into an active metabolite carbovir triphosphate (deoxyguanosine 5’triphosphate) dGTP.This active metabolite forbid the action of reverse transcriptase by spar with dGTP and inserted into viral DNA.
  • The growth of viral DNA gets concerned by the infusion of nucleotide which causes lack of OH molecule. OH, molecules are vital for the formation of 5’ to 3’ phosphodiester linkage which is guilty of chain extension.

PRECAUTION

  • The annoyance of HIV-1 infection: Patients should be considered earlier for the development of HIV infection or not. The influence of Taffic tablet for growing HIV-1 infection has not been assessing. These circumstances mostly occurred in patients who are HIV-1 co-infected.
  • Immune reconstitution syndrome: To overcome the problem by interrupting the treatment with Taffic . 
  • Renal deterioration worsening: Stop using Taffic tablet with drugs affecting the renal functions. Monitor the creatinine clearance value frequently. In severe conditions, CrCl below 30ml/min use of Taffic tablet should be avoided. Lactic acidosis & hepatic steatosis: Terminate the therapy using Taffic.
Taffic , Taffic tablet

DRUG INTERACTION

  • Taffic + P-GP or BCRP potent inhibitors: affect the consumption of TAF. Taffic + potent P-GP or BCRP inducers: decrease the consumption of TAF causes reducing=g the plasma concentration of TAF and certainly results as loss of effectiveness of Taffic. Taffic removal process occurs through kidneys; a combination of Taffic with drugs affecting the renal activity causes increasing the effect of concentration of ingredients of Taffic & concludes as achieve of adverse effects associated with these components.
  • Taffic tablet combines with drugs like Tipranavir/Ritonavir causes diminishing the effect of the concentration of TAF. Taffic concurrently used with anti-convulsions causes decreasing the effect of concentration of TAF. Taffic tablet concurrently used with anti-mycobacterium or st Johns wort causes decreasing the effect of concentration of TAF. Inhibition of both CYP3A4 and UGT1A1 by a co-administered drug could potentially lead to significant increases in BIC exposure, while potent induction of these enzymes may significantly reduce BIC exposure.

CONTRAINDICATION 

Taffic tablet has differed to patients with CrCl below 30ml/min Anaphylactic reactions are formed due to patients are contraindicated to the factor of Taffic.

OVERDOSAGE

The overdosage of Taffic tablet should be considered with hemodialysis. Emtricitabine should be evacuated by a 30% range after completing 3 hours of dialysis method. TAF should be removed by 54% of range after 4 hours dialysis session. Bictegravir is highly obligated to plasma proteins; it is strange that it will be necessarily removed by hemodialysis or peritoneal dialysis.

SIDE EFFECTS

Common side effects:

  • Depression
  • Abnormal dreams
  • Headache
  • Dizziness
  • Diarrhea
  • Feeling sick (nausea)
  • Tiredness (fatigue)

Uncommon side effects:

  • Anemia
  • vomiting
  • Stomach pain
  • Difficulty with digestion resulting in discomfort after meals (dyspepsia)
  • wind (flatulence)
  • swelling of the face, lips, tongue or throat (angioedema)
  • itching (pruritus)
  • Careless
  • Joint pain (arthralgia)
  • Suicidal behavior
  • Tension
  • sleep disorders

PEDIATRIC

  • The efficiency & influence of Taffic should not be calculated in pediatric patients with weighing below 25kg.

GERIATRIC

  • The efficiency of Taffic tablet should not be estimated in clinical trials for geriatric patients at the age of above 65 years.

RENAL DAMAGE

  • The uses of Taffic should be prevented in patients with CrCl below 30ml/min.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/taffic.php

https://myapplepharma.com/taf-emtricitabine-bictegravir.php

Купить Pirfenex 200mg | Pirfenex 200mg цена лекарства

Pirfenex (Pirfenidone) 200 мг – это рецептурное лекарственное средство общего назначения, используемое для лечения людей с заболеванием легких, называемым идиопатическим фиброзом легких (IPF), от Cipla, одной из крупнейших фармацевтических компаний в Индии.

Pirfenex 200мг , Pirfenex 200мг таблетка

Стоимость Эсбриета и Пирфенидона:

  • Стоимость Esbriet в США составляет 9199 долларов США за 270 капсул.

Pirfenex Стоимость и цена:

  • Generic Pirfenidone цена «s только 5% от стоимости Pirfenidone в Развязанных Штатах.

Эсбриет Дозирование:

  • Начальная доза для взрослых Pirfenex 200мг три раза в день (600 мг / день) после еды. 
  • Постепенно увеличивайте дозу до 600 мг три раза в день (1800 мг / день) под наблюдением (согласно Рекомендациям по корректировке дозировки ниже). 
  • Кроме того, соответственно увеличивайте или уменьшайте дозу время от времени в зависимости от симптомов.

Рекомендации по корректировке дозировки

  • Pirfenex 200мг таблетка три раза в день (600 мг / день). Через 2 недели постепенно увеличивайте дозу
  • 200 мг одновременно. Желательно поддерживать или достигать конечной дозы 600 мг за один раз (1800 мг / день). 
  • Пациенты, которые пропускают лечение пирфенидоном в течение 14 дней или более, должны возобновить терапию, пройдя начальный режим титрования дозы (см. Рекомендации по корректировке дозы выше) до рекомендуемой суточной дозы. 
  • Для Pirfenex 200мг прерывания лечения менее чем 14 дней подряд дозу можно возобновить с предыдущей рекомендуемой суточной дозы без титрования.

Esbriet побочные эффекты и Pirfenex побочные эффекты ：

  • Эсбриет и Пирфенидон могут вызывать серьезные побочные эффекты, в том числе:
  • проблемы с печенью. Pirfenex 200мг таблетка нно позвоните своему врачу, если у вас есть необъяснимые симптомы, такие как пожелтение кожи или белой части ваших глаз (желтуха), темная или коричневая (чайного цвета) моча, Pirfenidone боль в верхней правой части области живота (живот), кровотечение или кровоподтеки легче, чем обычно, чувство усталости.
Pirfenex 200мг , Pirfenex 200мг таблетка

Ваш врач проведет анализ крови, чтобы проверить, как ваша печень работает во время вашего лечения с ESBRIET.

  • чувствительность к солнечному свету (светочувствительность) и сыпь. Смотрите «Чего следует Pirfenex 200мг избегать при принятии ESBRIET?»
  • проблемы с желудком. ESBRIET может вызвать проблемы с желудком, такие как тошнота, рвота, диарея, расстройство желудка, изжога и боль в животе. 
  • Скажите своему врачу сразу, если ваши проблемы с желудком ухудшатся или не исчезнут. 
  • Ваш доктор, возможно, должен изменить Вашу дозу ESBRIET. 
  • Pirfenex 200мг Наиболее распространенные побочные эффекты ESBRIET включают чувство усталости, бессонницу, инфекции верхних дыхательных путей, синусит, головную боль, головокружение, снижение веса и снижение или потерю аппетита.

Наши контакты

Телефон  : 8 (800) 5517717
                   +7 (958) 7568122
                 +919987711567
Эл. Адрес : info@applepharma.su
Веб-сайт   : https://applepharma.su/products/pirfenex-200mg

Купить Inbec | Inbec цена лекарства

Профиль препарата:
Режим действия:

  • Inbec 400мг содержат три антиретровирусных препарата, таких как абакавир 300+, ламивудин 300+, дутегравир 50 мг. 
  • Inbec 400мг Таблетка  используется для лечения ВИЧ-инфекции I типа. Таблетка Inbec 400 является предпочтительной для ВИЧ-инфекции, она неизлечима и не поддается профилактике. 
  • Inbec является ингибитором протеазы, назначаемым для ВИЧ-инфекции у взрослых, который замедляет распространение ВИЧ-инфекции в организме. 
  • Это работает, блокируя рост вируса ВИЧ.
Inbec 400мг , Inbec 400мг Таблетка

Kontakindatin Inbeka 400:

Inbec 400мг противопоказан пациентам, которые получают elbasvir & grazoprevir в то же время. Реакции гиперчувствительности dolutegravir возникают из-за того, что Inbec 400 противопоказан пациентам.

Побочный эффект Inbec 400:

  • тошнота
  • усталость
  • Боль в животе
  • рвота
  • Anemie adeacresed количество тромбоцитов
  • Повышенный креатинин сыворотки
  • диарея
  • Инфекция верхних дыхательных путей

Предупреждение и меры предосторожности:

  • Потеря вирусологических эффектов
  • Inbec 400мг представляет собой комбинацию из трех препаратов с фиксированной дозой; есть вероятность сопротивления. Контролируйте пациента часто.
  • Нервная проблема
  • Уменьшите проблему, давая Inbec 400 перед сном натощак.
  • Повреждение эмбриона плода
  • Inbec 400мг противопоказан при беременности.
  • Проблемы с кожей
  • Тяжелые реакции гиперчувствительности происходят во время терапии Inbec 400. Предоставление общих мер поддержки предотвратит проблему.

Пропущенная доза

  • Inbec 400мг Таблетка представляет собой комбинацию из трех препаратов; Следует соблюдать осторожность во время терапии с Inbec 400 таблеток. 
  • Пожалуйста, проконсультируйтесь с врачом. Поддерживайте регулярный режим дозирования. 
  • Избегайте dolutegravir  пропущенной дозы, если это возможно. Не принимайте таблетки Inbec 400 самостоятельно.
Inbec 400мг , Inbec 400мг Таблетка

Побочные эффекты от Inbec 400:

  • изжога
  • головная боль
  • кожная сыпь
  • Боль в спине
  • Изменения вкуса
  • кашель
  • отек
  • головокружение
  • Запор

Условия хранения:

  • Хранить в прохладном и закрытом контейнере.

Наши контакты

Телефон  : 8 (800) 5517717
                   +7 (958) 7568122
                   +919987711567
Эл. Адрес : info@applepharma.su
Веб-сайт   : https://applepharma.su/products/inbec

Ledihep | Ledipasvir/Sofosbuvir | Anti viral drugs

  • Ledihep tablet should be used for both adults & pediatric patients with the age of 12 years or older or weight of at least 35kg. 
  • Used for; Genotype I, 4, 5, or 6 with compensated cirrhosis or without cirrhosis Genotype 1 infection with compensated cirrhosis or without cirrhosis Liver transplantation condition, genotype 1 with decompensated cirrhosis by use of ribavirin Genotype 1 or 4 without cirrhosis or with compensated cirrhosis by use of ribavirin Pediatric patients, HCV infection related to genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis.
Ledihep , Ledihep tablet

DOSAGE

  • The usual advised dose of Ledihep is one tablet should be administered as once a day. In HIV-1 co infected patients, Ledihep dosage consideration is; Patient without cirrhosis: (adult or pediatric of 12 years of age or older with genotype I, IV, V or VI Chronic HCV) The prescribed dose of Ledihep is one tablet should be taken orally as a single dose for 12 weeks

Genotype I

  • Without cirrhosis or compensated cirrhosis: Ledihep should be taken alone as a single dose followed for 12 weeks
  • Therapy experienced without cirrhosis: Ledihep should be taken as a single agent for once a day for 12 weeks
  • Therapy experienced with compensated cirrhosis: Ledihep tablet should be used for 24 weeks
  • In decompensated cirrhosis: Ledihep should be combined with ribavirin to be used, followed for 12 weeks

Genotype I to IV

  • In liver transplantation patients with compensated cirrhosis or without cirrhosis: Ledihep tablet should be combined with ribavirin for 12 weeks.

Genotype IV, V or VI :

  • Ledihep tablet should be administered alone for 12 weeks for Without cirrhosis or with compensated cirrhosis patients: On the basis of body weight the dose of ribavirin should be calculated <75kg: 1000mg; ≥75kg: 1200mg Ribavirin should be administered with food. Ledihep should be administered with or without food.

PHARMACOKINETICS

Peak plasma concentration of Ledihep :

  • Sofosbuvir: 0.8 to 1 hour & GS331007: 3.5 to 4 hours; Ledipasvir: 4 to 4.5 hours No effect produced, while Ledihep should be administered with or without food.

Plasma protein binding capacity of Ledihep :

Metabolism of Ledihep :

  • Sofosbuvir: hepatic metabolism with cathepsin A, or carboxyl esterase 1 & ledipasvir: mediated by CYP1A2, 2C8, 2C9, 2C19, 2D6 & 3A4.

Elimination of Ledihep :

  • Major route of elimination is through urine & feces. Ledipasvir through urine by 87%; Sofosbuvir through urine by 80%, feces by 14% & exhaled air by 3.5%

Half life period of Ledihep :

WORK AS

Ledipasvir is a solid prohibitor of perpetual hepatitis C viral relating non structural 5A protein which is a viral phosphoprotein. The essential part of ledipasvir in hostile to viral action instrument; Restraint of; Replication Virion assembly Secretion The mechanism of sofosbuvir associated with against viral movement is; Sofosbuvir is prohibitor of nucleotide analogue of hepatitis C viral disease identified with non basic 5B polymerase. This catalyst is in charge of interceding the HCV RNA duplication. The dynamic type of sofosbuvir is in triphosphate shape, which included diminishing the common cell uridine nucleotide and is coordinated by HCV RNA polymerase into the broadened RNA preliminary strand, which is closed in viral chain end.

SAFETY MEASURES

Hepatitis B reoccurrence :

  • This condition is mostly occurs in patients who are undergoing anti-viral therapy & fail to receive the anti-hepatitis B viral treatment. Monitor the HBsAg & anti-HBc counts before the therapy Hepatic function test should be performed Start the anti-hepatitis B treatment.

Bradycardia :

  • This severity is due to combination of amiodarone with Ledihep treatment. To avoid the problem patient ECG should be monitored. Patient should be counseled before initiate the treatment about the exposure of risk due to amiodarone. Provide supportive management.

Drug interactions :

  • The combination of Ledihep with P-gp inducers (potent), causes decreasing the plasma concentration of component of Ledihep.

Risk due to ribavirin :

  • Ribavirin causes fetal damage and leads to death. Contraindicated to pregnancy

PEDIATRIC

Genotype I

  • Without cirrhosis or with compensated cirrhosis: Ledihep should be administered orally afor 12 weeks. Therapy experienced without cirrhosis: Ledihep should be administered orally for 12 weeks. Therapy experienced compensated cirrhosis: Ledihep tablet should be administered orally for 12 weeks.

Genotype IV, V or VI

Therapy naïve or experienced without cirrhosis or with compensated cirrhosis: Ledihep tablet should be administered orally for 12 weeks. Renal impairment patients; Ledihep dosage adjustment should not be allowed in severe renal damaged condition. Due to greater exposure of sofosbuvir metabolite causes final stage of renal disease (ERSD).

DRUG INTERACTION

  • Ledihep , an inhibition of P-gp or BCRP drug transporters, this concomitant use causes increase intestinal absorption of these substrates. 
  • Ledihep + P-gp strong inducers lead to diminish the Ledihep tablet plasma concentration causes loss of therapeutic efficacy of Ledihep. 
  • Ledihep + warfarin causes alteration in INR values, monitor the prothrombin time during this combination. Ledihep + gastric regulators, causes diminishing Ledipasvir plasma concentration, do not administer Ledihep tablet concurrently with gastric regulators. Ledihep + anti-arrhythmic agents lead to produce plasma concentration elevation of these drugs. Ledihep + anti-convulsants or anti-mycobacterials may cause depletion of plasma concentration of Ledihep. 
  • Ledihep + anti-retroviral drugs, increases the plasma concentration of these drugs. Ledihep + st Johns wort causes decreasing the plasma concentration of Ledihep.
  • Ledihep + HMG CoA reductase inhibitors cause elevation of plasma concentration of these drugs.

OVERDOSAGE

  • The over dosage condition should be overcome by; Provide supportive management. Monitor the manifestations. 
  • Treated by Hemodialysis Ledipasvir does not eliminate by hemodialysis process, because of ledipasvir has large protein binding capacity. 
  • The circulating metabolite of  Sofosbuvir is eliminated from the body by processing with hemodialysis with the range of 54%.

CONTRAINDICATION

  • Ledihep with ribavirin is contraindicated to pregnancy condition Hypersensitivity reactions produces, if patients are contraindicated to the component present in the Ledihep.

MISSED DOSE

  • In case of missed dose occurrence during the therapy, patient must be consult with medical practitioner and follow the instructions. Maintain the regular dosing schedule.

SIDE EFFECTS

  • Fatigue, Headache, Nausea, Diarrhea, Insomnia, Elevation of bilirubin, Elevation of lipase, Elevation of creatine kinase, Severe bradycardia, HBV reactivation, Chest pain, Dizziness, Trouble in breathing.
Ledihep , Ledihep tablet

WARNING

  • The regular antagonistic delivered amid or after finish of treatment are; Introduction of HBV restoration in HCV/HBV co contaminated patients. T
  • o avoid the problem by counting the patients HBsAg & anti-HBc values before initiate the treatment with Ledihep . 
  • Monitor the hepatic function test periodically before, during & after completion of treatment. Patient should be provided with supportive management for preventing the hepatitis B viral infection reoccurrence.

CONTACT DETAILS

Phone :+91-9987711567
Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com 

Website : https://myapplepharma.com/ledihep.php

Ledifos | Ledipasvir/Sofosbuvir

  • Ledifos tablet should be used for both adults & pediatric patients with the age of 12 years or older or weight of at least 35kg. 
  • Used for; Genotype I, 4, 5, or 6 with compensated cirrhosis or without cirrhosis Genotype 1 infection with compensated cirrhosis or without cirrhosis Liver transplantation condition, genotype 1 with decompensated cirrhosis by use of ribavirin Genotype 1 or 4 without cirrhosis or with compensated cirrhosis by use of ribavirin Pediatric patients, HCV infection related to genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis.
Ledifos , Ledifos tablet

DOSAGE

  • The usual advised dose of Ledifos is one tablet should be administered as once a day. In HIV-1 co infected patients, Ledifos dosage consideration is; Patient without cirrhosis: (adult or pediatric of 12 years of age or older with genotype I, IV, V or VI Chronic HCV) The prescribed dose of Ledifos is one tablet should be taken orally as a single dose for 12 weeks.

Genotype I

  • Without cirrhosis or compensated cirrhosis: Ledifos should be taken alone as a single dose followed for 12 weeks
  • Therapy experienced without cirrhosis: Ledifos should be taken as a single agent for once a day for 12 weeks
  • Therapy experienced with compensated cirrhosis: Ledifos tablet should be used for 24 weeks
  • In decompensated cirrhosis: Ledifos should be combined with ribavirin to be used, followed for 12 weeks

Genotype I to IV

  • In liver transplantation patients with compensated cirrhosis or without cirrhosis: Ledifos tablet should be combined with ribavirin for 12 weeks.

Genotype IV, V or VI :

  • Ledifos tablet should be administered alone for 12 weeks for Without cirrhosis or with compensated cirrhosis patients: On the basis of body weight the dose of ribavirin should be calculated <75kg: 1000mg; ≥75kg: 1200mg Ribavirin should be administered with food. Ledifos should be administered with or without food.

PHARMACOKINETICS

Peak plasma concentration of Ledifos :

  • Sofosbuvir : 0.8 to 1 hour & GS331007: 3.5 to 4 hours; Ledipasvir : 4 to 4.5 hours No effect produced, while Ledifos should be administered with or without food.

Plasma protein binding capacity of Ledifos :

Metabolism of Ledifos :

  • Sofosbuvir : hepatic metabolism with cathepsin A, or carboxyl esterase 1 & Ledipasvir : mediated by CYP1A2, 2C8, 2C9, 2C19, 2D6 & 3A4.

Elimination of Ledifos :

  • Major route of elimination is through urine & feces. Ledipasvir through urine by 87%; Sofosbuvir through urine by 80%, feces by 14% & exhaled air by 3.5%

Half life period of Ledifos :

  • Sofosbuvir 0.4%, GS-331007: 27 hours & ledipasvir: 47 hours.

WORK AS

  • Ledipasvir is a solid prohibitor of perpetual hepatitis C viral relating non structural 5A protein which is a viral phosphoprotein. The essential part of ledipasvir in hostile to viral action instrument; Restraint of; Replication Virion assembly Secretion The mechanism of sofosbuvir associated with against viral movement is; Sofosbuvir is prohibitor of nucleotide analogue of hepatitis C viral disease identified with non basic 5B polymerase. This catalyst is in charge of interceding the HCV RNA duplication. The dynamic type of sofosbuvir is in triphosphate shape, which included diminishing the common cell uridine nucleotide and is coordinated by HCV RNA polymerase into the broadened RNA preliminary strand, which is closed in viral chain end.

SAFETY MEASURES

Hepatitis B reoccurrence :

  • This condition is mostly occurs in patients who are undergoing anti-viral therapy & fail to receive the anti-hepatitis B viral treatment. Monitor the HBsAg & anti-HBc counts before the therapy Hepatic function test should be performed Start the anti-hepatitis B treatment.

Bradycardia :

  • This severity is due to combination of amiodarone with Ledifos treatment. To avoid the problem patient ECG should be monitored. Patient should be counseled before initiate the treatment about the exposure of risk due to amiodarone. Provide supportive management.

Drug interactions :

  • The combination of Ledifos with P-gp inducers (potent), causes decreasing the plasma concentration of component of Ledifos.
  • Risk due to ribavirin :
  • Ribavirin causes fetal damage and leads to death. Contraindicated to pregnancy

IN PEDIATRIC

Genotype I

  • Without cirrhosis or with compensated cirrhosis: Ledifos should be administered orally afor 12 weeks. 
  • Therapy experienced without cirrhosis: Ledifos should be administered orally for 12 weeks.
  • Therapy experienced compensated cirrhosis: Ledifos tablet should be administered orally for 12 weeks.

Genotype IV, V or VI

  • Therapy naïve or experienced without cirrhosis or with compensated cirrhosis: Ledifos tablet should be administered orally for 12 weeks. Renal impairment patients; Ledifos dosage adjustment should not be allowed in severe renal damaged condition. Due to greater exposure of sofosbuvir metabolite causes final stage of renal disease (ERSD).

DRUG INTERACTION

  • Ledifos , an inhibition of P-gp or BCRP drug transporters, this concomitant use causes increase intestinal absorption of these substrates. Ledifos + P-gp strong inducers lead to diminish the Ledifos plasma concentration causes loss of therapeutic efficacy of Ledifos. Ledifos + warfarin causes alteration in INR values, monitor the prothrombin time during this combination. Ledifos + gastric regulators, causes diminishing Ledipasvir plasma concentration, do not administer Ledifos tablet concurrently with gastric regulators. Ledifos + anti-arrhythmic agents lead to produce plasma concentration elevation of these drugs. Ledifos + anti-convulsants or anti-mycobacterials may cause depletion of plasma concentration of Ledifos. Ledifos + anti-retroviral drugs, increases the plasma concentration of these drugs. Ledifos + st Johns wort causes decreasing the plasma concentration of Ledifos. Ledifos + HMG CoA reductase inhibitors cause elevation of plasma concentration of these drugs.

OVERDOSAGE

  • The over dosage condition should be overcome by; Provide supportive management. Monitor the manifestations. 
  • Treated by Hemodialysis Ledipasvir does not eliminate by hemodialysis process, because of ledipasvir has large protein binding capacity. The circulating metabolite of sofosbuvir is eliminated from the body by processing with hemodialysis with the range of 54%.

CONTRAINDICATION

Ledifos with ribavirin is contraindicated to pregnancy condition Hypersensitivity reactions produces, if patients are contraindicated to the component present in the Ledifos.

MISSED DOSE

In case of missed dose occurrence during the therapy, patient must be consult with medical practitioner and follow the instructions. Maintain the regular dosing schedule.

Ledifos , Ledifos tablet

SIDE EFFECTS

Fatigue, Headache, Nausea, Diarrhea, Insomnia, Elevation of bilirubin, Elevation of lipase, Elevation of creatine kinase, Severe bradycardia, HBV reactivation, Chest pain, Dizziness, Trouble in breathing.

WARNING

The regular antagonistic delivered amid or after finish of treatment are; Introduction of HBV restoration in HCV/HBV co contaminated patients. To avoid the problem by counting the patients HBsAg & anti-HBc values before initiate the treatment with Ledifos . Monitor the hepatic function test periodically before, during & after completion of treatment. Patient should be provided with supportive management for preventing the hepatitis B viral infection reoccurrence.

CONTACT DETAILS

Phone :+91-9987711567
Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com 

Website : https://myapplepharma.com/ledifos.php

Hepbest 25mg (Mylan) tablet

  • Tenofovir Alafenamide is an anti-hepaciviral & anti-retroviral medicine. In HIV infected patients, Hepbest 25mg tablet is not used alone and it may combine with some other anti-retroviral drugs like Emtricitabine, cobicistat, or darunavir. At first, Hepbest 25mg is belongs to anti-retroviral (nucleoside reverse transcriptase inhibitor), now Hepbest has anti-hepaciviral property which is used against hepatitis B viral infection
Hepbest 25mg , Hepbest 25mg tablet

USES

  • Prior usage of Hepbest 25mg tablet , used in HIV-1 infection Hepbest tablet is also indicated for the treatment of hepatitis B viral infection, by reducing the advancement of virus Hepbest used in chronic hepatitis B infection, is non-curable but it can able to prevent the viral transmission

CATEGORY

  • Anti-retroviral drug
  • Anti-hepaciviral drug

Hepbest TABLET

  • The usual dosage of Hepbest 25mg tablet is, one tablet containing 25mg of Tenofovir Alafenamide should be taken as a single dose Hepbest tablet should be administered with food In creatinine clearance range <15ml/min, Hepbest 25mg tablet is not recommended In decompensated cirrhosis: Hepbest should not be recommended Before initiating the therapy: Patients should examine HIV-1 infection for recommending combination of other anti-retroviral drugs in HIV-1 positive patients.

WORKS

  • Hepbest 25mg –Tenofovir Alafenamide (TAF) TAF is a prodrug of tenofovir (parent drug) At first, TAF is penetrating into hepatic cells because it has lipophilic cell permeable capacity. After enters into the cells, TAF undergoes hydrolysis by using carboxylesterase-1 and to formed as tenofovir. Tenofovir involved in intracellular metabolism, which is phosphorylated into tenofovir triphosphate. Tenofovir triphosphate is considered as an active metabolite which has anti-viral property and integrated into viral DNA by hepatitis B reverse transcriptase enzyme and leads to inhibits viral production thus results as termination of viral chain.

How the body works for Hepbest tablets

  • After an oral administration, absorption of Hepbest 25mg tablet occurs rapidly. The peak plasma time occurs within 0.48 hours The effect of food while taking Hepbest tablet is includes as; With high fat meal, the effect of Tenofovir Alafenamide is 1.65 Hepbest is highly bound to human plasma protein nearly 80% The blood plasma ration is 1.0 Metabolism of Tenofovir Alafenamide is occurs with the aid of cathepsin A, carboxylesterase-1 The half life period of Tenofovir Alafenamide is 0.51 hour Excretion occurs through urine <1%; feces 31.7%

WARNING & PRECAUTION

  • After cessation of anti-hepatitis B therapy by using with Hepbest tablet, concluded in serious intense aggravation of hepatitis B infection. To avoid this adverse condition in the patients, liver function should be observed frequently.
  • Exposure of reinforcement of HIV-1 antagonism in HBV/HIV-1 co infected patients In HIV infected patients, combinational therapy is suggested for avoiding this condition in co-infected patients. Check the HIV antibody in all HBV infected patients before starting the therapy.
  • New commencement Hepbest 25mg tablet and worsening of renal damage Patient with low renal function capability, stop the Hepbest tablet therapy immediately and monitored the serum phosphorus, serum creatinine, urine protein, urine glucose and creatinine clearance frequently
  • Lactic acidosis or serious hepatomegaly with steatosis If this condition occurred in the patients, immediately discontinue the therapy and provide safety measures

DRUG INTERACTION

Hepbest combined with P-gp or BCRP strong inhibitors, results as alteration of absorption of Tenofovir Alafenamide P-gp or BCRP inducers, combined with Hepbest 25mg tablet leads to cause loss of therapeutic effect of Hepbest 25mg with P-gp or BCRP moderate inhibitors results as absorption elevation thus causes plasma concentration of Tenofovir Alafenamide Hepbest tablets combined with anti-convulsants (phenytoin, carbamazepine, or Phenobarbital), anti-mycobacterials (rifampin, rifapentine, or rifabutin) or herbal products (st Johns wort) causes depletion in effect of concentration of Hepbest

OVER DOSAGE

In over dosage condition, two steps follows :

  • Examine the deposition of toxicity and symptoms occurred due to over dosage
  • Hemodialysis, a method involved in eradicating the over dosage of Hepbest with separation coefficient of 54%

MISSED DOSE

  • Once missed dose occurred, patient must consult with medical practitioner and follow the instruction. 
  • On another way, missed dose should be skipped and proceed from regular dosing schedule.
Hepbest 25mg , Hepbest 25mg tablet

SIDE EFFECTS

Important adverse effects;

  • Lactic acidosis or severe hepatomegaly with steatosis
  • Reactivation of hepatitis B viral infection in worsening condition after the therapy
  • Renal damage occurs
  • Some of undesirable effects;
  • Headache
  • Fatigue
  • Cough
  • Nausea
  • Back pain
  • Abdominal pain
  • Reduction in bone mineral density
  • Glycosuria
  • Creatine kinase elevation
  • Amylase lipase elevated.

CONTACT DETAILS

Phone :+91-9987711567
Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com 

Website : https://myapplepharma.com/hepbest-25mg.php

Hepcinat 400 & Natdac 60 mg |Anti viral drugs

Hepcinat + Natdac tablet are hostile to viral medicine Hepcinat + Natdac tablets are single measurements treatment, it is a doctor prescribed medication utilized by the patients just under the information of restorative expert who are all around rehearsed Daclatasvir isn’t utilized alone, for better activity it ought to be joined with Sofosbuvir tablet. In some condition Hepcinat + Natdac is joined with ribavirin, a hostile to viral pharmaceutical utilized as a part of decompensated (Child Pugh B or C) cirrhosis

Hepcinat + Natdac

PRESCRIBED FOR

The primary sign of Hepcinat + Natdac is; This mix tablets are utilized to treat the constant hepatitis C viral disease caused by genotype I or III The significant restriction happened while utilizing Hepcinat + Natdac tablets are lessening of steady virological reaction rate in hepatitis C genotype I or III contaminated patients.

PHARMACOLOGY

The activity of Hepcinat + Natdac tablet are occurred by involving in some mechanism;

SOFOSBUVIR

Sofosbuvir containing Sofosbuvir has hostile to hepaciviral movement, which is specifically acting medication displays its activity by disallowing NS5B RNA dependent RNA polymerase protein; fundamental for hepatitis viral duplication. Sofosbuvir is processed to frame uridine triphosphate, a fundamental dynamic metabolite which uncovered a hostile to viral action. The mixture of this dynamic metabolite into hepatitis viral RNA with the assistance of NS5B polymerase and causes viral chain cessation

DACLATASVIR

Daclatasvir containing Daclatasvir removes hostile to viral action by restricting NS5A protein which is needful in viral generation and virion collection

DOSAGE

Hepcinat + Natdac tablets are given with or without food, in the condition of chronic hepatitis C viral infection originated by genotype I or III Hepcinat + Natdac is single dose therapy

Dosage regimens

Daclatasvir normally is not used alone treatment, it is combined with Sofosbuvir The suggested dosage of Hepcinat + Natdac is one tablet should be taken as a single dose If Sofosbuvir is discontinued, Daclatasvir also get stopped Genotype I Patient suffered without cirrhosis or with compensated cirrhosis: The recommended usual dosage of Hepcinat + Natdac is one tablet should be taken as a single dose with or without food In decompensated cirrhosis patients: Hepcinat + Natdac should be altogether with ribavirin as a single dose

Genotype III

Patient suffered without cirrhosis or with compensated cirrhosis: The recommended usual dosage of Hepcinat + Natdac is one tablet should be administered as a single dose with or without food In decompensated cirrhosis patients: Hepcinat + Natdac should be concomitant with ribavirin as a once a day The dosage of ribavirin; The hemoglobin level of patients, dose can be calculated on basis of body weight. Below 75kg: The dosage is 1000mg of ribavirin; suggested for genotype I or III 600mg of ribavirin as an primary dose and followed as 1000mg/per Slightly 75 kg: The dose of 1200mg of ribavirin administrated In decompensated cirrhosis given as twice daily. The safety and efficacy of Daclatasvir has not been established <18 years Sofosbuvir used in ≥12 years or weight of ≥35kg

PHARMACOKINETICS

Absorption :

  • The maximum plasma concentration of Daclatasvir tablets occurs within 2 hours The mean bioavailability of Daclatasvir is 67% The maximum plasma concentration of Sofosbuvir tablets occurs within the range of 0.5 to 2 hours relatively. The nourishment won’t makes any variety in retention of Hepcinat + Natdac tablets, might be taken with or without sustenance

Distribution :

  • Volume of distribution in Daclatasvir tablet is 47L Daclatasvir bounds to human plasma protein nearly 99% Blood to plasma ratio of Sofosbuvir is relatively 0.7 The Sofosbuvir  bounds to human plasma protein nearly 61 to 65%

Metabolism :

  • Sofosbuvir metabolized in liver and formed as dynamic metabolite uridine triphosphate, metabolism experienced with the assistance of cathepsin A or carboxylesterase 1 Daclatasvir digestion happened with the assistance of CYP3A4

Elimination :

  • Nearly 88% of Daclatasvir is eliminated via feces; 53% as parent form; 6.6% eliminated through urine. 
  • Sofosbuvir metabolites are excreted through 80% in urine, 14% in feces & 2.5% in exhaled air The terminal half life period of Sofosbuvir is reaches at 0.51 hours; Daclatasvir half life period is 12 to 15 hours

DRUG INTERACTION

  • While consolidating Hepcinat + Natdac with solid CYP3A inducers causes loss of virological response rate of Daclatasvir CYP3A solid inducers like st Johns wort, rifampin, phenytoin or carbamazepine In the event that Sofosbuvir joins with P-gp or BCRP inhibitors prompts cause rise of Sofosbuvir plasma focus. Hepcinat + Natdac tablets attendant with amiodarone causes genuine symptomatic bradycardia. Hepcinat + Natdac tablets attendant with hostile to convulsants, against mycobacterials or natural items like st Johns wort causes diminish as a result of fixation Hepcinat + Natdac with HMG CoA reductase inhibitors, this mix prompts because expanding the presentation of these medications (statins)

Dosage adjustment in drug interaction

  • If concurrent use with strong CYP3A inhibitors, the dosage of Daclatasvir is reduced to 30mg while co administration Concurrent use with moderate CYP3A inducers, the dosage of Daclatasvir increased to 90mg Concomitant use of Daclatasvir with CYP3A strong inducers should be avoided, it is contraindicated

MISSED DOSE

  • Both Hepcinat + Natdac tablets are single dosage treatment, if tolerant neglects to take the measurement of these tablets, must counsel the doctor and take the measurement inside the time according to the direction given by therapeutic expert Generally the missed measurement ought to be skipped and take after the standard dosing plan

CONTRAINDICATION

  • A few contraindications happens while utilizing Hepcinat + Natdac tablet In decompensated cirrhosis, joins with ribavirin contraindicated in pregnancy condition Some anaphylactic response happens if patients are contraindicated to the segments show in Hepcinat + Natdac

PRECAUTIONS

While taking Hepcinat + Natdac tablets, with CYP3A solid inducers causes loss of remedial reaction of Hepcinat + Natdac tablets. Stay away from this accompanying to diminish the unfriendly impacts Hepcinat + Natdac causes genuine bradycardia while simultaneous use with amiodarone, to keep this condition some elective solution is given or ends the amiodarone if conceivable. Insight the patients about the introduction of bradycardia amid the treatment Utilizing Hepcinat + Natdac with ribavirin, ought not be prescribed in pregnancy condition as a result of creating fetal harm because of ribavirin

SIDE EFFECTS

The most common side effects occurred during the therapy;

  • Headache, Loss of appetite, Irritability, Neutropenia, Anemia, Chills, Influenza like symptoms, Pyrexia, Myalgia, Pancytopenia, Fatigue, Nausea, Diarrhea, Elevation of lipase, Cardiac problems like symptomatic bradycardia , Insomnia, Pruritus, Asthenia, Rashes, on the grounds that almost 99% of medication limited to human plasma protein .
Hepcinat + Natdac

OVERDOSAGE

The over dose of Hepcinat + Natdac tablet are happened because of missed measurement , if once finished dose happens the patients must be observed oftentimes for support of harmfulness and give wellbeing measures Hemodialysis is a technique used to take out the part from body, Sofosbuvir evacuates with partition coefficient of 54% though Daclatasvir is hazardous

CONTACT DETAILS

Phone :+91-9987711567

Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com 

Website : https://myapplepharma.com/x-vir-0.5mg.php

Tafero-EM 25 mg / 200 mg

  • Tafero EM is an antiretroviral drug containing two eminent ingredients known as; Tenofovir alafenamide fumarate Emtricitabine Tenofovir alafenamide nucleotide translation inhibitor and a transcription inhibitor. 
  • Ambos son provides effective action against potential VIH-1 infections, without any additional conditions, alone to prevent HIV infection with VIH-1 and SIDA. 
  • In  Tafero EM Tablet   , TAF Form. Emtricitabine is a synthetic fluoride derivative of thiacytidine.
Tafero EM   ,  Tafero EM Tablet

INDICATION

DOSAGE

This is a  condition for oral treatment orally in oral form. Important points; Before starting treatment, the patient should examine to detect cases of hepatitis B infection no. The patient’s renal values ​​should Research on the creation of creatinines, including in vivo. Tafero-MS should be determined in teenascents, pediatric patients weighing at least 25 kg and the creatinine clearance of the patients should be greater than 30 ml / min. Tafero-EM does not require special use, and in the first place – 30 ml / min. Tafero EM Tablet  must be Administered with food or without food.

PHARMACOLOGY

  • Tafero EM  contains Tenofovir alafenamide   fumarate and emtricitabine TAF null knot – pharmacologically simple inverted transcriptase inhibitors, including controversial by profession. It is changed as a functional structure in vivo, known as tenofovir. 
  • Tenofovir experimental materials on the construction of buildings and structures. 
  • El Atomo de Aguas es Basico-para-el-de-enlas-de-enlas-phosphodiester. Tenofovir is of great importance for all areas related to ADN and is an interference between 5 ‘a 3’ Member States and is important for the prolongation of ADN. 
  • Tenofovir Comprometido Con; Chain scrap DNA stretch end Stops the interpretation of Emtricitabine proviral DNA; Emtricitabine  imagine orders de to deter el chemical viral Reverse transcriptase di es essential pair creation viral. Emtricitabine Inclie; Chain elimination Stops the increase in HIV RNA duplicates Serves to emulate viral load

What the body does to Tafero-EM after administration

  • Отчеты об устном обращении: о поглощении  Tafero EM  should occur very quickly and the maximum plasma time of tenofovir is 1 hour. The average absolute bioavailability of emtricitabine is производит 93%. Food doses do not affect the abstention of Tafero-MS. 
  • The Natural Organization for the Protection of Human Rights, Tafero-EM is; TAF: 80%; Emtricitabine: 4% of tafero-EM metabolism; TAF is hydrolysed to an active form called Tenofovir by the use of cathepsin A or carboxylesterase 1. 
  • El  metabolism de la  Tenofovir  alafenamide biotransformation mediad. El Período de Semivida Terminal de Tafero-EM es; TAF: 0.51 h. Emtricitabine: 10 h. As a result of the removal of tafero-EM, traumatic activation occurs and the filtering membrane of the kidney proceeds.

SAFETY MEASURES

  • Hepatitis B gravity: Hepatitis B virus infection not. 
  •  It has not evaluated the effectiveness of  Tafero EM Tablet  for Advanced Hepatitis B infection. 
  • This condition mainly occurred in patients infected with HIV-1 / HBV. Immune System Reconstitution Syndrome: The Problem of Super-Pretoria Intercommunity Relations with Tafero-EM. 
  • Renal failure: on-duty kidney Tafero-EM with medications that affect kidney functions. Monitoring the situation in the field of creativity and freedom. Under conditional conditions,  CrCl and below 30 ml / min should be avoided .  Tafero EM . Lactic acidosis and hepatic steatosis: discontinue therapy with Tafero-MS

DRUG INTERACTION

  • Tafero EM  + P-gp o BCRP inhibitory potentials: afectan la abscicin de TAF. Inductive potentials from P-gp o BCRP from Tafero-EM +: reduced TAF absorption in terms of reduction = final plasma concentration and the final result from determining the effectiveness of Tafero-EM. 
  • El  Process de elimination de Tafero EM occurs traves – de – los – kidneys, l combination de Tafero – EM con medications Affecting la activity renal causes un increase del Effect de concentration de Ingredients de Tafer de de de de de de de de de de Tafero effects Adverse Associates Estos Components. 
  • Tafero EM Tablet  combines with medications such as tipranavir / ritonavir and decreases the effect of концентрат TAF. Tafero-EM used simultaneously with anticonvulsants causes a decrease in the effect of концентрат TAF. Tafero-EM used simultaneously with anti-mycobacteria or St. John’s wort causes a decrease in the effect of концентрат TAF.

CONTRAINDICATION

  • Tafero EM   is contraindicated for patients with cyclic below 30 ml / min. This may be due to inconsistencies related to components such as Tafero-EM.

OVERDOSE

  • Tafero EM overdose   should be treated with hemodialysis. 
  • Sorry, but don’t forget that you have 30% of the vote. 3 hours work. THIS IS A TABLE OF DIPLICATES IN 54% OF DECADE REST FROM 4 DECADES.

PEDIATRIC

GERIATRIC

  • The no power of  Tafero EM  should not be evaluated in clinical trials couple geriatric patients scammers Age over 65 years.

RENAL DAMAGE

  • Ce  The OVO of   Tafero EM Tablet should be avoided  in cyclic patients Below 30 ml / min.
Tafero EM  ,   Tafero EM Tablet

SIDE EFFECTS

  • Lactic acidosis, hepatic steatosis, severe exacerbation of hepatitis B, regenerative immunity syndrome, new outbreak or aggravation of renal failure.

Some side effects are:

  • Increased cholesterol levels, increased serum creatinine level, effects of density – CD + cells varies.

CONTACT DETAILS

Phone: + 91-9987711567
E-mail :  applepharmaceutical@gmail.com 
E-mail :  info@myapplepharma.com
Sitio Website:  https://myapplepharma.com/tafero-em.php

Tafnat Tenofovir Alafenamide 25 mg | Antiviral drugs

  • Tenofovir Alafenamide  is an anti-hepaciviral and antiretroviral medication. 
  • In HIV-infected patients, Tafnat not used alone and can be combined with some other antiretroviral medications such as Emtricitabine, cobicistat or darunavir. 
  • At first, Tafnat belongs to the antiretroviral (nucleoside reverse transcriptase inhibitor), now Tafnat has an antihepaciviral property that is used against hepatitis B viral infection
Tafnat  ,  Tafnat tablet

USES

  • Prior use of the  Tafnat tablet  , used in HIV-1 infection The Tafnat tablet is also indicated for the treatment of viral hepatitis B infection, by reducing the progression of the Tafnat virus used in chronic hepatitis B infection, it is not curable but can prevent viral transmission

CATEGORY

  • Antiretroviral drug
  • Antihepaciviral drug

TAFNAT TABLET 

  • The usual dose of  Tafnat tablet  is, a tablet containing 25 mg of  Tenofovir Alafenamide  should be taken as a single dose. Tafnat tablet should be administered with food. Recommended Before starting therapy: patients should examine HIV-1 infection to recommend the combination of other antiretroviral drugs in patients with HIV-1 positive.

WORKS

  • Tafnat  – Tenofovir Alafenamide  (TAF) TAF is a prodrug of tenofovir (original drug) At first, TAF penetrates liver cells because it has a capacity permeable to lipophilic cells. 
  • After entering the cells, TAF is subjected to hydrolysis by the use of carboxylesterase-1 and is formed as tenofovir. 
  • Tenofovir participates in intracellular metabolism, which is phosphorylated in tenofovir triphosphate. 
  • Tenofovir triphosphate is considered an active metabolite that has antiviral properties and is integrated into viral DNA by the reverse transcriptase enzyme of hepatitis B and leads to inhibit viral production, resulting in the termination of the viral chain.

How the body works for Tafnat tablets

  • After an oral administration, the absorption of the  Tafnat tablet  occurs rapidly. The maximum plasma time occurs within 0.48 hours. The effect of food while taking the Tafnat tablet is included as; With high-fat food, the effect of  Tenofovir Alafenamide  is 1.65 Tafnat is highly bound to human plasma proteins almost 80% The blood plasma ration is 1.0 Metabolism of  Tenofovir Alafenamide  is produced with the help of cathepsin A, carboxylesterase- 1 The half-life period of Tenofovir Alafenamide is 0.51 hours Excretion occurs through urine <1%; stool 31.7%

WARNING AND CAUTION

  • After cessation of hepatitis B therapy by using the  Tafnat tablet  , it concluded in a severe and severe worsening of hepatitis B infection. To avoid this adverse condition in patients, liver function should be observed frequently.
  • Exposure of reinforcement of HIV-1 antagonism in patients infected with HBV / HIV-1 In patients infected with HIV, combined therapy is suggested to prevent this condition in coinfected patients. Check the HIV antibody in all patients infected with HBV before starting therapy.
  • New onset and worsening of renal damage Patient with low renal function capacity, discontinue Tafnat tablet therapy immediately and control serum phosphorus, serum creatinine, urinary protein, urine glucose and creatinine clearance frequently
  • Lactic acidosis or severe hepatomegaly with steatosis If this condition occurred in patients, immediately discontinue treatment and provide safety measures.

DRUG INTERACTION

  • Tafnat combined with strong inhibitors of P-gp or BCRP, results as an alteration of the absorption of the inducers of Tenofovir Alafenamide P-gp or BCRP, combined with the  Tafnat tablet  leads to the loss of the therapeutic effect of Tafnat Tafnat with moderate inhibitors of P-gp or BCRP as Therefore, the increased absorption produces plasma concentrations of  Tenofovir Alafenamide  Tafnat in tablets combined with anticonvulsants (phenytoin, carbamazepine or phenobarbital), antimycobacterials (rifampicin, rifapentin or rifabutin) or herbal products (St herb Johns) that cause depletion in the effect of concentration. from Tafnat 

MISSED DOSE

  • Once the missed dose has occurred, the patient should consult a doctor and follow the instructions. 
  • Otherwise, the missed dose should be omitted and proceed from the regular dosing schedule.

OVERDOSE

In overdose conditions, follow two steps:

  • Examine the toxicity deposit and the symptoms due to overdose
  • Hemodialysis, a method involved in the eradication of Tafnat  overdose  with a separation coefficient of 54%.
Tafnat  ,   Tafnat tablet

SIDE EFFECTS

Important adverse effects;

  • Lactic acidosis or severe hepatomegaly with steatosis
  • Reactivation of worsening hepatitis B viral infection after therapy
  • Kidney damage occurs.
  • Some of the undesirable effects;
  • Headache
  • Fatigue
  • Tos
  • Nausea
  • Back pain
  • Abdominal pain
  • Bone mineral density reduction.
  • Glucosuria
  • Elevation of creatine kinase
  • Amylase lipase elevated.

CONTACT DETAILS

Phone: + 91-9987711567

Email: applepharmaceutical@gmail.com 
Email: info@myapplepharma.com

Website:  https://myapplepharma.com/tafnat-25mg.php

Design a site like this with WordPress.com
Get started